Corneal Toxicity

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Corneal Toxicity trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingNot Applicable

NCT01793168

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, i…

United States, Australia20,000 participantsStarted 2010-07

All recent trials (8 shown)

CompletedPhase 1/2

NCT02592330

Limbal Stem Cell Deficiency (LSCD) Treatment With Cultivated Stem Cell (CALEC) Graft

The main aim of the study is to determine the safety and feasibility of a cultivated autologous limbal epithelial cell (CALEC) transplantation in the treatment…

United States23 participantsStarted 2016-08-01

Treatment: Biopsy to collect limbal epithelial stem cells that will be cultivated into a graft, Cultivation of Limbal epithelial cells into a graft

CompletedNot Applicable

NCT05887206

Corneal Toxicity in Patients Treated by Belantamab Mafodotin

Belantamab Mafodotin is the first antibody conjugate targeting B-cell maturation antigen (BCMA) in relapsed or refractory multiple myeloma (RRMM). It is used in…

France43 participantsStarted 2022-05-02

Treatment: Collection of datas

Corneal Toxicity

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

All recent trials (8 shown)

Limbal Stem Cell Deficiency (LSCD) Treatment With Cultivated Stem Cell (CALEC) Graft

Corneal Toxicity in Patients Treated by Belantamab Mafodotin

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

All recent trials (8 shown)

Limbal Stem Cell Deficiency (LSCD) Treatment With Cultivated Stem Cell (CALEC) Graft

Corneal Toxicity in Patients Treated by Belantamab Mafodotin

Topical Infliximab in Autoimmune Eyes With Keratoprosthesis

Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epiderm…

Cysteamine Eye Drops to Treat Corneal Crystals in Cystinosis

A Comparison of Infection Rates Between Two Surgical Sites

Effect of Moxifloxacin Versus Gatifloxacin on Corneal Epithelium Following Pterygium Excision